Clinical Trial: A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjogren's Syndrome

U.S., July 28 -- ClinicalTrials.gov registry received information related to the study (NCT07727486) titled 'A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjogren's Syndrome' on July 21.

Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of ICP-488 in participants with primary Sjogren's syndrome (pSjS).

Study Start Date: Aug., 2026

Study Type: INTERVENTIONAL

Condition: Primary Sjogren's Syndrome

Intervention: DRUG: ICP-488 Tablets

Specified dose on specified days

DRUG: ICP-488 Placebo

Specified dose on specified days

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd...